請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33104
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 游張松 | |
dc.contributor.author | "Yen Chung-Yang, M.D." | en |
dc.contributor.author | 閻中原 | zh_TW |
dc.date.accessioned | 2021-06-13T04:25:09Z | - |
dc.date.available | 2006-08-09 | |
dc.date.copyright | 2006-08-09 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-22 | |
dc.identifier.citation | 中文部分
1. 中華民國科學技術年鑑, 行政院國家科學委員會,民93.10 2. 王大維,「200家製藥公司調查結果出爐:藥廠尋求外援 - 產業價值分工時代來臨」,MD News生技與醫療器材報導 第75期。 3. 王博彥,「各層級醫療院所門診藥物交互作用分析- 以全民健康保險學術研究資料庫為例」, 臺北醫學大學醫學資訊研究所/碩士論文,民92 4. 江睿玲,「中草藥藥物資源之研究」,元培科學技術學院/生物技術研究所,碩士論文民94。 5. 行政院衛生署,「藥品非臨床試驗安全性規範」行政院衛生署,民89.6 6. 李經緯,「中西醫結合與中醫國際化趨勢」,J Chin Med 15(3): 137-150, 2004 7. 林宜信,「臺灣中醫藥願景」,行政院衛生署中醫藥委員會簡介,行政院衛生署中醫藥委員會,民93.8 8. 林宜信,「臺灣中醫藥整合與前瞻」行政院衛生署中醫藥委員會 9. 郝宏恕,「民眾對中醫藥之認知態度及消費行為特質之研究」,中國醫藥學院醫務管理研究所。 10. 國科會生物處,「生物科技發展計畫/子計畫一:農業生物技術國家型科技計畫」,2002.02 11. 張仁平,「台灣中草藥專利保護之回顧與前瞻」(2003/7/18) 12. 梁文俐,「中草藥安全性之研究」台北醫學院藥學研究所,博士論文民88 13. 黃博偉,「生技製藥的價值鏈:FDA 臨床實驗和藥物開發成本的關係」。(ITIS 2004/06 ). 14. 廖怡蘭,「生技醫藥產業全球競爭力之發展與願景」。第四屆全國工業發展會議第三分組引言報告,2001.5.7。 15. 廖美智,「台灣中藥產業現況」,主要國家產經政策動態季刊,第四期 九十年十二月 16. 鄭瑞雄,「中草藥可能的不良反應」,台灣醫界 2005,8月,第48卷第8期。 17. 閻中原,「中草藥治療重要傳染病之作用機制評估技術平台」研究計劃期中報告。民95.2 英文部分 1. Adam Smith (1776). 'Of the Division of Labour', The Wealth of Nations, pp. 30-35. 2. Berry, M.J.A. & Linoff, G..S. 2004. Data Mining Techniques (2nd ed.). Indianapolis, IN: Wiley Publishing. 3. Cbidanand. A., 'Data Mining' An Industrial Research Perspective, IEEE Computer Science & Engineering. Pp.6-9 (1998) 4. Chen, M. S., J. Han. and P. S. Yu.1996. Data Mining:An Overview from Database Perspective. IEEE Transactions Knowledge and Data Engineering: 5. Cohen, M.H., 'Legal and ethical issues relating to use of complementary therapies in pediatric hematology/oncology'. J Pediatr Hematol Oncol. 2006 Mar;28(3):190-3. 6. Dobrin, J., 'Essays in public health and preventive medicine. A call to Pharms: the need for tighter FDA regulation of the neutraceutical industry'. Mt Sinai J Med. 2006 Mar;73(2):565-6. 7. Fayyad, U. M., Piatetsky-Shapiro, G., Smyth, P. and Uthurusamy, R., editors. 1996. Advances in Knowledge Discovery and Data Mining. AAAI/MIT Press, Menlo Park, CA. 8. Gurib-Fakim, A. 'Medicinal plants: traditions of yesterday and drugs of tomorrow.' Molecular aspects of medicine. 2006 Feb;27(1):1-93. 9. Herman ZS. 'Progress and dilemma of contemporary clinical pharmacology.', International journal of clinical pharmacology and therapeutics. 2005 Jan;43(1):43-50. 10. Hruschka, H. and Martin Natter 'Comparing Performance of Feedforward Neural and K-Means for Cluster-Based Market Segmentation: European Journal of Operational Research, 114, pp 346-353, (1999) 11. Joseph. A. and Noel Bryson. 'Parametric Linear Programming and Cluster Analysis', European Journal of Operational Research. 111 pp582-588(1998) 12. MacPherson H, Liu B. 'The safety of Chinese herbal medicine: a pilot study for a national survey.' J Altern Complement Med. 2005 Aug;11(4):617-26. 13. Niimi H., Patumraj S., Han J.Y., 'Asian traditional medicine (ATM): recent progress based on scientific evidences.' Clinical hemorheology and microcirculation, 2006;34(1-2):85-8 14. Suter E., Verhoef M., O'Beirne M. ' Assessment of the information needs and use of information resources on complementary and alternative medicine by Alberta family physicians.' Clinical and investigative medicine. 2004 Dec;27(6):312-5. 15. Usama M. Fayyad, Gregory Piatetsky-Shapiro, and Padhraic Smyth. From Data Mining to Knowledge Discovery: An Overview. In Usama M. Fayyad, Gregory Piatetsky-Shapiro, Padhraic Smyth, and Ramasamy Uthurusamy, editors, Advances in Knowledge Discovery and Data Mining 16. W. J. FRAWLEY, G. PIATETSKI-SHAPIRO y C. J. MATHEUS. 'Knowledge Discovery in Databases: An Overview'. Knowledge Discovery in Databases, G. Piatetsky-Shapiro y W. Frawley, AAAI-MIT Press, Menlo Park, California, 1991. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33104 | - |
dc.description.abstract | 中草藥近年來逐漸在歐美各國流行,2005年全球中草藥銷售額已超過二百億美元。中國、日本、韓國、德國及美國分別是亞洲、歐洲及美洲三個地區發展中草藥的代表,全球中草藥也以這三個地區為主。台灣近年來也積極投入,希望能在中草藥領域創造國家優勢。行政院通過『加強生物技術產業推動方案』、成立了『生物技術與製藥工業發展推動小組』,著重於生物技術集中草藥的開發,期望將台灣發展成具特色之生技醫藥產業發展中心
中草藥國際化發展面臨最大的問題,就是品質的掌握及嚴謹的臨床實驗。中草藥臨床研究較之西方醫藥臨床研究其複雜度與技術門檻均高出許多。中草藥之原料取材自天然植物,無論是原料自體變異性、基源、藥理活性、活性成分都僅依賴經驗傳承的漢方古籍提供不完整的線索,也缺乏嚴謹的科學驗證。 本研究從中草藥臨床前研究探討中草藥國際化的問題。可以發現中草藥在臨床前的安全驗證與品質一致性是攸關中草藥未來發展的關鍵因素。以知識合作的角度探討,可以發現獨立研究中心的垂直型研究可以發揮專業化的效率但卻無法創造合作的效益。必須建立效率化的專業臨床服務又能兼顧知識合作的效益,才能符合中草藥臨床前基礎研究的未來需求。 本研究利用” 中草藥抗病毒機制高通量篩選平台”的個案調查,從基礎研究的角度分析配合產業價值鏈的定位。本研究發現在中、西醫邏輯架構迴異的情況下,硬性將中醫藥學納入西醫學的框架中,可能會造成中草藥的價值喪失。基礎研究過程的知識庫與知識平台的管理能力。透過標準程序的臨床前檢驗,累積中草藥相關的驗證數據,才能構建出對中草藥有實質效益的知識管理平台。而研究平台在產業價值鏈的定位與貢獻,會因為學界與產業界的認知缺口造成現有研究成果無法對產業價值鏈產生效益。因此,除了技術上的合作或移轉外,知識合作成為另一項必須關注的重點。開放性的研究平台與技術加上知識的整體合作,才能使中草藥基礎研究發揮實質效益,順利的與產業價值鏈接軌,提高中草藥國際化發展的可行性。 | zh_TW |
dc.description.abstract | In recent years, botanical drugs have become more and more popular in western countries. Global sales for botanical drugs exceeded 20 billion US dollars in 2005. China, Japan, South Korea, Germany, and the United States are the primary countries for the development of botanical drugs in Asia, Europe, and America, which are the leading areas for botanical drugs worldwide. Taiwan has also invested in the research and development of botanical drugs in recent years in order to create a competitive edge for the country in the field of botanical drugs. The Executive Yuan approved the Promotion Plan for the Biotechnology Industry and founded the Biotechnology and Pharmaceutical Industries Program Office to transform Taiwan into a primary development center for the biotechnology and pharmaceutical industries.
The most challenging issues for globalization of the development of botanical drugs lie in the areas of quality control and stringent clinical trials. The complexity and technical barriers for clinical trials of botanical drugs are much higher than for those of western medicine. The raw materials for botanical drugs come from natural plants. Therefore, the autonomic diversities, sources, pharmacological activities, and active components of the raw materials depend on the sharing and learning of experiences from ancient Chinese medical texts, to help deal with incomplete information that lacks stringent scientific validation. This study investigated critical issues for the globalization of botanical drugs from pre-clinical studies of botanical drugs. Pre-clinical safety evaluation and quality conformity for botanical drugs were identified as the critical factors for the development of botanical drugs in the future. Investigation from the perspective of knowledge collaboration revealed that vertical research by independent research centers could utilize professional efficiency, but did not create the benefit of collaboration. It was deemed necessary to establish efficient professional clinical services and employ knowledge collaboration to meet future demands in the fundamental pre-clinical study of botanical drugs. The present study used a platform of high-throughput screening for the antiviral mechanism of botanical drugs to analyze the position of the value chain of supportive industries from the perspective of fundamental research. The present study discovered that simply fitting Chinese medicine into the framework of western medicine, combining the separate architectures of Chinese medicine and western medicine, would result in a loss of value for botanical drugs. A knowledge management platform of substantial value to botanical drugs can be constructed based on the management competence of a knowledge database and platform during a course of fundamental research and through standard procedures for pre-clinical analysis to accumulate validated data related to botanical drugs. The position and contribution of the research platform in the value chain of supportive industries may not provide any benefit for the accomplishment of current research due to the misperceptions of the academic community and the industrial sector. Therefore, knowledge collaboration has become another critical factor to be taken into consideration along with technical collaboration or transfer. An open research platform and integrated collaboration of technology and knowledge will allow fundamental research of botanical drugs to provide substantial value. As a result, research can combine with the industrial value chain to increase the feasibility of the international development of botanical drugs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T04:25:09Z (GMT). No. of bitstreams: 1 ntu-95-P93743014-1.pdf: 930869 bytes, checksum: 201d098aff2c4c2fe2401d0d133f2c86 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 第一章 緒論--------------------------------------------1
第一節 研究背景------------------------------------1 第二節 研究動機------------------------------------3 第三節 研究問題與目的------------------------------6 第四節 研究範圍與限制------------------------------9 第五節 論文架構------------------------------------11 第二章 理論與文獻探討----------------------------------12 第一節 中草藥臨床前研究與關鍵因素------------------12 第二節 知識採礦-醫學臨床技術的累積價值-------------27 第三節 分工合作理論與產業價值鏈--------------------36 第四節 本章小結------------------------------------43 第三章 研究方法----------------------------------------45 第一節 研究說明------------------------------------45 第二節 研究架構------------------------------------45 第三節 研究設計------------------------------------47 第四節 研究過程------------------------------------48 第四章 中草藥產業現況問題與機會探討--------------------49 第一節 中草藥產業現況與展望------------------------49 第二節 國際臨床研究的現況與利基--------------------58 第三節 台灣中草藥產業發展的障礙與機會--------------63 第五章 平台的效益評估與分析----------------------------70 第一節 個案調查背景說明----------------------------70 第二節 個案成果分析—技術層面----------------------77 第三節 營運模型分析—產業價值鏈--------------------86 第六章 結論與建議--------------------------------------96 第一節 研究結論------------------------------------96 第二節 改善建議------------------------------------99 第三節 對後續研究者之建議--------------------------100 參考文獻-----------------------------------------------101 | |
dc.language.iso | zh-TW | |
dc.title | 中草藥研發技術平台的效益實證 | zh_TW |
dc.title | An Empirical Study On The Effectiveness of Botanical drugs Research Platform | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張銀益,張溫良,蔡揚宗,陳安 | |
dc.subject.keyword | 中草藥,臨床前研究平台,知識合作,產業價值鏈, | zh_TW |
dc.subject.keyword | botanical drugs,pre-clinical studies,knowledge collaboration,industrial value chain, | en |
dc.relation.page | 105 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-22 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 高階公共管理組 | zh_TW |
顯示於系所單位: | 高階公共管理組 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 909.05 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。